You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1–infected patients with severe chronic kidney disease
|
|---|---|
| Published in |
Liver International, March 2018
|
| DOI | 10.1111/liv.13674 |
| Pubmed ID | |
| Authors |
Faisal M. Sanai, Abdullah S. Alghamdi, Ahmad A. Afghani, Khalid Alswat, Adnan AlZanbagi, Mosfer N. Alghamdi, Abdallah AlMousa, Mohammed Aseeri, Abdullah M. Assiri, Mohamed A. Babatin |
| Abstract |
Limited data has shown high efficacy of co-formulated ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in the treatment of hepatitis C virus (HCV) genotype (GT)-4, and combined with dasabuvir (DSV) in GT1 patients, with chronic kidney disease (CKD) stage 4-5 (<30 mL/min/1.73 m2 ). We assessed real-world safety and efficacy of OBV/PTV/r ± DSV in GT1 and 4-infected patients. In this observational cohort (n=67), we enrolled stage 4-5 CKD treatment-naïve or Peginterferon/RBV-experienced GT4-infected patients (n=32) treated for 12-24 weeks with OBV/PTV/r ± RBV, and plus DSV in GT1 patients (n=35, including 3 with GT1/4 co-infection). RBV was dosed by physician discretion between 200 mg weekly - 200 mg daily. Primary endpoints were SVR12, calculated on intention-to-treat (ITT) basis, and occurrence of serious adverse events. The mean age of the cohort was 45.7±12.7 years, 50.7% were female, 20.9% had cirrhosis, 35.8% were treatment-experienced and 97% were on hemodialysis. Three patients (F4) received 24 weeks treatment, 2 with GT4, and 1 with GT1a; and 19.4% were treated without RBV, including 9 GT1, and 4 GT4. Overall, 65 (97.1%) patients achieved SVR12, including 100% of those with a post treatment follow-up (modified ITT analysis). Of the 2 patients without SVR12, one died from sepsis-related complications and the other from a myocardial infarction 2 weeks after completing therapy. Grade 3-4 anemia occurred in 8.9%. A 12-week regimen of OBV/PTV/r ± DSV with or without RBV is highly effective with a favourable safety profile amongst GT4 and GT1 patients with CKD stages 4-5. SVR12 rates were high regardless of patient characteristics. This article is protected by copyright. All rights reserved. |
X Demographics
The data shown below were collected from the profiles of 22 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Saudi Arabia | 10 | 45% |
| Thailand | 1 | 5% |
| Unknown | 11 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 16 | 73% |
| Scientists | 4 | 18% |
| Practitioners (doctors, other healthcare professionals) | 2 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 29 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 4 | 14% |
| Student > Bachelor | 4 | 14% |
| Student > Master | 2 | 7% |
| Student > Postgraduate | 2 | 7% |
| Researcher | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 15 | 52% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 17% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 10% |
| Environmental Science | 1 | 3% |
| Immunology and Microbiology | 1 | 3% |
| Agricultural and Biological Sciences | 1 | 3% |
| Other | 2 | 7% |
| Unknown | 16 | 55% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 April 2018.
All research outputs
#2,252,288
of 25,392,582 outputs
Outputs from Liver International
#142
of 2,941 outputs
Outputs of similar age
#46,992
of 343,654 outputs
Outputs of similar age from Liver International
#3
of 47 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,941 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 343,654 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.